A Study to Learn About the Single Dose Pharmacokinetics of Study Medicine Called Tilrekimig in Healthy Adults When Co-Mixed With rHuPH20

Part of paid clinical trials in New Haven, Connecticut.

Sponsor
Pfizer
Study ID
NCT07792941
Phase
PHASE1
Status
Recruiting
Apply to this trial

Conditions

  • Healthy

Eligibility Criteria

Sex
ALL
Age
18 Years - 65 Years
Healthy Volunteers
Accepted

Interventions

  • tilrekimig and rHuPH20 — DRUG
    subcutaneous injection

Study Details

This study aims to learn how the body handles tilrekimig when given with another medicine called recombinant human hyaluronidase PH20 (rHuPH20). rHuPH20 is approved to help some medicines be taken up by the body when they are given together as an injection (shot) under the skin.

Key Dates

First listed
Aug 28, 2026
Start date
Aug 27, 2026
Status verified
Sep 2026
Primary completion
Feb 11, 2027
Completion
Feb 11, 2027

Study Design

Enrollment
12 participants (estimated)
Allocation
NA
Intervention model
SINGLE_GROUP
Primary purpose
BASIC_SCIENCE

Arms

  • Experimental: tilrekimig and rHuPH20
    a single dose of co-mixed tilrekimig and rHuPH20

Primary Outcome Measure

Tilrekimig area under the serum concentration-time curve from time zero to infinity (AUCinf) [ Time Frame: pre-dose, hours 12, 24, 48, 72, and 96 hours post dose. Days 8, 15, 30, 45, 60, 90, 120, and 150 post -dose ]

Central Contacts

Locations (1)

FacilityCityStateZIPSite coordinators
New Haven Pfizer Clinical Research Unit (NH PCRU)New HavenConnecticut06511-

Find similar trials in New Haven, CT

By research site
New Haven Pfizer Clinical Research Unit (NH PCRU)· New Haven, CT

Related Studies